Ressources numériques en sciences humaines et sociales OpenEdition Nos plateformes OpenEdition Books OpenEdition Journals Hypothèses Calenda Bibliothèques OpenEdition Freemium Suivez-nous

ARM and NIIMBL Release Project A-Cell to Bring Quality by Design Principles to Cell-Based Therapy Manufacturing (Cell and Gene Therapy Catapult – Regulatory Round-up – October 2022)

The Alliance for Regenerative Medicine (ARM) and the National Institute for Innovation in Manufacturing BioPharmaceuticals (NIIMBL) has published Project A-Cell, a multistakeholder collaboration to incorporate Quality by Design (QbD) principles into cell-based therapy CMC programs as well as organized a six-part live webinar series highlighting specific A-Cell chapters which will culminate in a workshop in June of 2023. Please find more information on these events here.

See all of Catapult’s Regulatory Round-up for October 2022 here. Published on the 7th of November 2022.


OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (25 janvier 2023). ARM and NIIMBL Release Project A-Cell to Bring Quality by Design Principles to Cell-Based Therapy Manufacturing (Cell and Gene Therapy Catapult – Regulatory Round-up – October 2022). ELSIBI. Consulté le 16 mars 2026 à l’adresse https://doi.org/10.58079/o677


Vous aimerez aussi...

Laisser un commentaire

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *

This site uses Akismet to reduce spam. Learn how your comment data is processed.